PKD Clinical Trial - Safety Outcomes in Part A

• The Safety Review Committee (SRC) governing the Phase 1a/1b study has confirmed that single doses of PYC-003 up to and including 4 mg/kg in healthy volunteers were considered to be safe and well tolerated2 PERTH, Australia and SAN FRANCISCO, California – 19 December 2025 PYC Therapeutics Limited (ASX:PYC) (PYC or the Company) is a precision medicine Company dedicated to changing the lives of pat